TipHub

147.15

-4.32 -2.85%

As of 28 Jul 2026 · delayed

NSE Listed · Pharmaceuticals

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-09
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

IOL Chemicals & Pharmaceuticals Ltd. (IOLCP)

Volume: 9,92,986Avg Vol 1W: 14,10,204Avg Vol 1M: 74,10,54152W Range:67.19179.6
Market Cap₹4,319 Cr
Current Price₹147.15
Previous Close₹151.47
High / Low (52w)₹179.6 / ₹67.19
Volume9,92,986
Avg Vol (1W)14,10,204
Avg Vol (1M)74,10,541
Stock P/E81.3
Book Value₹61.27
Dividend Yield0.74%
ROE7.65%
ROA5.32%
Revenue (TTM)
Revenue Growth-2.51%
Profit Margin5.94%
Total Debt₹0 Cr
Shares Outstanding29 Cr
Face Value₹2
EPS (TTM)₹1.81
P/B2.4
Debt / Equity0.08
50 DMA₹140.3
200 DMA₹98.16
Day change-2.85%
SurveillanceLT-ASM · ASM 1
Price Chart
147.15 58.02% · 1Y
174686.6Cr
2025-07-29
2026-07-28

20-day avg volume: 72.0L shares

Pros
  • Company is almost debt-free.
  • Net profit is growing year over year.
Cons
  • Stock trades at a high P/E of 81.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹502 Cr₹526 Cr₹523 Cr₹528 Cr₹552 Cr₹568 Cr₹580 Cr₹619 Cr
EBITDA₹42 Cr₹30 Cr₹32 Cr₹49 Cr₹50 Cr₹44 Cr₹42 Cr₹74 Cr
Net Profit₹30 Cr₹19 Cr₹21 Cr₹31 Cr₹34 Cr₹30 Cr₹21 Cr₹53 Cr
EPS
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹526 Cr₹523 Cr₹2,102 Cr₹528 Cr₹552 Cr₹568 Cr₹580 Cr₹619 Cr
EBITDA₹30 Cr₹32 Cr₹153 Cr₹49 Cr₹50 Cr₹44 Cr₹42 Cr₹74 Cr
Net Profit₹19 Cr₹21 Cr₹101 Cr₹32 Cr₹34 Cr₹30 Cr₹21 Cr₹53 Cr
EPS3.44
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹1,170 Cr₹1,610 Cr₹1,962 Cr₹2,022 Cr₹2,244 Cr₹2,382 Cr
Total Liabilities₹356 Cr₹350 Cr₹570 Cr₹514 Cr₹633 Cr₹694 Cr
Equity₹814 Cr₹1,260 Cr₹1,392 Cr₹1,508 Cr₹1,612 Cr₹1,688 Cr
Total Debt₹0 Cr₹0 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹522 Cr₹156 Cr₹169 Cr₹332 Cr₹197 Cr
Investing₹-317 Cr₹-121 Cr₹-120 Cr₹-191 Cr₹-154 Cr
Financing₹-58 Cr₹-2 Cr₹-4 Cr₹-92 Cr₹46 Cr
Free Cash Flow₹522 Cr₹156 Cr₹169 Cr₹332 Cr₹197 Cr
Shareholding
Promoter 62.28% Institutions 5.31% Public 32.42%
Efficiency & Working Capital
ROCE8.8%
Interest Coverage10.4
Dividend Payout
Debtor Days90 d
Inventory Days63 d
Payable Days75 d
Cash Conversion Cycle78 d
Working Capital Days153 d
Shareholding Details

As of 2026-06-30

Promoter62.3%
FII4.9%
DII0.4%
Institutions5.3%
Public32.4%
Promoter Pledge0%
No. of Shareholders1,19,311
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters48.2%48.2%48.2%48.2%48.2%52.6%52.6%52.6%52.6%52.6%57.5%62.3%
FIIs2.3%2.2%1.4%1.4%1.6%1.5%1.5%2.6%2.2%2.1%1.7%4.9%
DIIs0.4%0.4%0.3%0.1%0.1%0.1%0.1%0%0%0%0%0.4%
Public49.1%49.3%50.1%50.3%50.1%45.8%45.8%44.8%45.1%45.3%40.8%32.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,5311,31,5501,19,311
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Nm Merchantiles LimitedShareholding of Promoter and Promoter Group21.9%6.42 Cr
Maya Devi Polycot LimitedShareholding of Promoter and Promoter Group21.8%6.39 Cr
Ncvi Enterprises LimitedShareholding of Promoter and Promoter Group16.6%4.87 Cr
Varender GuptaShareholding of Promoter and Promoter Group2%59,79,325
Dimple GuptaShareholding of Promoter and Promoter Group0%0
Vikas GuptaShareholding of Promoter and Promoter Group0%0
Abhiraj GuptaShareholding of Promoter and Promoter Group0%0
Varinder Gupta (huf)Shareholding of Promoter and Promoter Group0%5,500
Vikas Gupta (huf)Shareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Varinder GuptaManaging Director2025
Vikas GuptaJoint Managing Director2025
Rajender Mohan MallaChairman & Independent Director2025
Harpal SinghIndependent Director2025
Abhay Raj SinghCompany Sec. & Compli. Officer2025
Kushal Kumar RanaDirector (Works)2025
SHARAD TYAGIIndependent Director2025
Abhiraj GuptaExecutive Director2025
Rajni JhaIndependent Director2025
Segments — Product
SegmentRevenueShare
Chemicals₹867 Cr41.7%
Drugs₹1,212 Cr58.3%
Segments — Geography
RegionRevenueShare
India₹1,523 Cr73.3%
Switzerland₹51 Cr2.5%
Spain₹55 Cr2.7%
Rest of the world₹449 Cr21.6%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2805959
Corporate Actions
TypeDateValueRemark
dividend2026-02-17₹1 (50%)Interim
forthcomingBook ClosureAGM
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202520024107132
202520024107132
2025000000
Insider / Designated-Person Trades

5 recent disclosure(s)

NCVI Enterprises LimitedAcquisition · 4,04,305
Mayadevi Polycot LimitedAcquisition · 54,197
NCVI Enterprises LimitedAcquisition · 7,00,000
NCVI Enterprises LimitedAcquisition · 7,00,000
Mayadevi Polycot LimitedAcquisition · 6,54,123
Substantial Acquisitions (SAST)

2 disclosure(s)

Off Market25/06/2026 · 1,40,83,195
Off Market17/10/2025 · 1,15,78,195
Company Information
Incorporated1986
ChairmanRajender Mohan Malla
AuditorAshwani & Associates
🌐 www.iolcp.com

📍 Trident Complex, Raikot Road Barnala, Sangrur, Punjab, 148101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search